PHAXIAM Therapeutics
Anne-Cécile Fumey is currently the Vice President of Human Resources at Phaxiam Therapeutics, a dual-listed biotech company. Previously, she served as the International Human Resources Director at CLASQUIN, managing HR strategies and integration of new acquisitions in multiple countries. Prior to that, she held roles at National Bank of Canada and BD, focusing on HR management and compensation & benefits. With a background in Political Science, Economy & Finance, Anne-Cécile continues to expand her expertise through educational programs such as a Certificate in Independent Administrator.
This person is not in any offices
PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.